Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours

European Journal of Cancer

Volumn 36, Issue 1, 2000, Pages 128-136

  Szepeshazi, K ^a,b   Schally, A V ^a,b   Groot, K ^a   Armatis, P ^a   Hebert, F ^a   Halmos, G ^a,b  

^a Endocrine   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AgNOR; GH RH antagonists; IGF I; IGF I receptor; IGF II; Pancreatic cancer

Indexed keywords

GONADORELIN ANTAGONIST; MZ 4 71; MZ 5 156; NITROSAMINE; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; DRUG EFFECT; FEMALE; NONHUMAN; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYRIAN HAMSTER;

ANIMALS; CELL DIVISION; CRICETINAE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MESOCRICETUS; MICE; MICE, NUDE; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; SERMORELIN;

EID: 0033963319     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00230-0     Document Type: Article

References (44)

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer Statistics, 1998. CA Cancer J. Clin. 48:1998;6-29.
2. McGrath P.C., Sloan D.A., Kenady D.E. Surgical management of pancreatic carcinoma. Semin. Oncol. 23:1996;200-213.
3. Lionetto R., Pugliese V., Bruzzi P., Rosso R. No standard treatment is available for advanced pancreatic cancer. Eur. J. Cancer. 31A:1995;882-887.
4. Perilli D., Mansi C., Savarino V., Celle G. Hormonal therapy of pancreatic carcinoma. Int. J. Pancreatol. 13:1993;159-168.
5. Schally A.V. Hypothalamic hormones. from neuroendocrinology to cancer therapy Anti-Cancer Drugs. 5:1994;115-130.
6. Szepeshazi K, Halmos G, Schally AV, et al. Growth inhibition of experimental pancreatic cancers and sustained reduction of epidermal growth factor receptors during therapy with hormonal peptide analogues. J Cancer Res Clin Oncol 1999, 125, 444-452.
7. Hayakawa H., Kawarada Y., Mizumoto R., Hibasami H., Tanaka M., Nakashima K. Induction and involvement of endogenous IGF-I in pancreas regeneration after partial pancreatectomy in the dog. J. Endocrinol. 149:1996;259-267.
8. Bergmann U., Funatomi H., Yokoyama M., Berger H.G., Korc M. Insulin-like growth factor I overexpression in human pancreatic cancer. evidence for autocrine and paracrine roles Cancer Res. 55:1995;2007-2011.
9. Christofori G., Naik P., Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature. 369:1994;414-417.
10. Bergmann U., Funatomi H., Kornmann M., Ishiwata T., Berger H.G., Korc M. Insulin-like growth factor II activates mitogenic signaling in pancreatic cancer cells via IRS-1. in vivo evidence for an islet-cancer cell axis Int. J. Oncol. 9:1996;487-492.
11. Rubin R., Baserga R. Biology of disease. Insulin-like growth factor-I receptor. Lab. Invest. 73:1995;311-331.
12. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins. biological actions Endocrine Rev. 16:1995;3-34.
13. Zarandi M., Kovacs M., Horvath J.E.et al. Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH). Peptides. 18:1997;423-430.
14. Pinski J., Schally A.V., Groot K.et al. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J. Natl. Cancer Inst. 87:1995;1787-1794.
15. Pinski J., Schally A.V., Jungwirth A.et al. Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH). Int. J. Oncol. 9:1996;1099-1105.
16. Jungwirth A., Schally A.V., Pinski J.et al. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br. J. Cancer. 17:1997;1585-1592.
17. Szende B., Srkalovic G., Schally A.V., Lapis K., Groot K. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Cancer. 65:1990;2279-2290.
18. Pour P., Mohr U., Cardesa A., Althoff J., Kruger F.W. Pancreatic neoplasms in an animal model. morphological, biological, and comparative studies Cancer. 36:1975;379-389.
19. Szepeshazi K., Schally A.V., Cai R.-Z., Radulovic S., Milovanovic S., Szoke B. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters. Cancer Res. 51:1991;5980-5986.
20. Kyriazis A.P., McCombs III W.B., Sandberg A.A., Kyriazis A.A., Sloane N.H., Lepera R. Establishment and characterization of human pancreatic adenocarcinoma cell line SW-1990 in tissue culture and the nude mice. Cancer Res. 43:1983;4393-4401.
21. Qin Y., Ertl T., Cai R.-Z., Horvàth J.E., Groot K., Schally A.V. Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP. Int. J. Cancer. 63:1995;257-262.
22. Szepeshazi K., Korkut E., Schally A.V. Decrease in the AgNOR number in Dunning R 3327 prostate cancer after treatment with LH-RH agonist and antagonist. Am. J. Pathol. 138:1991;1273-1277.
23. Munson P.J., Rodbard D. Ligand. a versatile computerized approach for characterization of ligand-binding systems Anal. Biochem. 107:1980;220-239.
24. Lamharzi N., Schally A.V., Koppan M., Groot K. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc. Natl. Acad. Sci. USA. 95:1998;8864-8868.
25. Plumb J.A., Milroy R., Kaye S.B. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2yl)-2, 5-diphenyltetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res. 49:1989;4435-4440.
26. Rall L.B., Scott J., Bell G.I. Human insulin-like growth factor I and II messenger RNA. isolation of complementary DNA and analysis of expression Methods Enzymol. 146:1987;239-248.
27. Murabe H., Simatsu A., Ihara C.et al. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas. quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction J. Neuroendocrinol. 8:1996;605-610.
28. Leung K.-C., Rajkovic I.A., Peters E., Markus I., Van Wyk J.J., Ho K.K.Y. Insulin-like growth factor I and insulin down-regulate growth hormone (GH) receptors in rat osteoblasts. evidence for a peripheral feedback loop regulating GH action Endocrinology. 137:1996;2694-2702.
29. Ohmura E., Okada M., Onoda N., Kamiya Y., Murakami H., Tsushima T. Insulin-like growth factor I and transforming growth factor as autocrine growth factors in human pancreatic cancer cell growth. Cancer Res. 50:1990;103-107.
30. Harrison L.E., Blumberg D., Berman R.et al. Effect of human growth hormone on pancreatic carcinoma growth, protein, and cell cycle kinetics. J. Surg. Res. 61:1996;317-322.
31. Evans J.D., Eggo M.C., Donovan I.A., Bramhall S.R., Neoptolemos J.P. Serum levels of insulin-like growth factors (IGF-I and IGF-II) and their binding protein (IGFBP-3) are not elevated in pancreatic cancer. Int. J. Pancreatol. 22:1997;95-100.
32. Toretsky J.A., Helman L.J. Involvement of IGF-II in human cancer. J. Endocrinol. 149:1996;367-372.
33. Xu Y.P., Chedrese P.J., Thacker P.A. Growth hormone as an amplifier of insulin-like growth factor-I action. potential oestradiol accumulation J. Endocrinol. 152:1997;201-209.
34. Baserga R. The insulin-like growth factor I receptor. a key to tumor growth Cancer Res. 55:1995;249-252.
35. D'Ambrosio C., Ferber A., Resnicoff M., Baserga R. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res. 56:1996;4013-4020.
36. Blakesley V.A., Stannard B.S., Kalebic T., Helman L.J. Role of the IGF-I receptor in mutagenesis and tumor promotion. J. Endocrinol. 152:1997;339-344.
37. LeRoith D., Werner H., Beitner-Johnson D., Roberts C.T. Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Rev. 16:1995;143-163.
38. Mohan S., Baylink D.J. Editorial. insulin-like growth factor (IGF)-binding proteins in serum do they have additional roles besides modulating the endocrine IGF actions? J. Clin. Endocrinol. Metab. 81:1996;3817-3820.
39. Ceda G.P. IGFs in the feedback control of GH secretion. hypothalamic and/or pituitary action? J. Endocrinol. Invest. 18:1995;734-737.
40. Lee P.D.K., Baker B.K., Liu F., Kwan E.Y.W., Hintz R.L. A homologous radioimmunoassay for rat insulin-like growth factor-I (IGF-I). Implications for studies of human IGF-I physiology. J. Clin. Endocrinol. Metab. 81:1996;2002-2005.
41. Crawford B.A., Martin J.I., Howe C.J., Handelsman D.J., Baxter R.C. Comparison of extraction methods for insulin-like growth factor-I in rat serum. J. Endocrinol. 134:1992;169-176.
42. Lobie P.E., Breipohl W., Waters M.J. Growth hormone receptor expression in the rat gastrointestinal tract. Endocrinology. 126:1990;299-306.
43. Kovacs M., Zarandi M., Halmos G., Groot K., Schally A.V. Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats. mechanisms of action Endocrinology. 137:1996;5364-5369.
44. Csernus V.J., Schally A.V., Kiaris H., Armatis P. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc. Natl. Acad. Sci. USA. 96:1999;3098-3103.